
Opinion|Videos|March 13, 2025
Early Clinical Trial Data for Rilzabrutinib in CSU and Future Study Directions
Panelists discuss how rilzabrutinib shows promise in phase 2 trials with rapid improvements in disease activity scores (UAS7 and ISS7) starting from week 1 and a favorable safety profile, setting expectations for the upcoming phase 3 studies to confirm these initial findings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Now let’s shift over to talk about rilzabrutinib, which is currently in phase 2 development. What are we seeing from the findings so far?
- significant ISS7 changes seen as early as week 1
- Rapid onset and favorable safety profile
- Can you comment on what you’d like to see for rilzabrutinib as it enters phase 3 studies?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes
2
Prevalence and Recognition of Hypercortisolism
3
Distinguishing CSU From Chronic Inducible Urticaria Subtypes
4
METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy
5


























































































